Andrew Feinberg

Don't let a stock's stumbles blind you to its long-term potential.

It’s been a strange year for high-yielding stocks.

Baby boomers approaching retirement might think of buying a Tesla.

Now I plan to invest a chunk of the family portfolio in index funds—oh, the horror!

Seth Klarman was prescient in recognizing that the genomics revolution would supercharge the biotech industry.

When investors like Carl Icahn and Bill Ackman turn the heat on management, shareholders stand to benefit.

Buying more shares makes sense when nothing about a company has changed except the price of its stock.

Bank of America has made great progress in cutting costs and settling legal claims for shoddy mortgage securities.

What I like about BioDelivery Sciences is not so much that there are many ways to win as that there are almost no ways to lose.

Many investors are fighting the last war, in which every tech titan inevitably gets its comeuppance.

Keep an eye (and ear) on the details for hints that a company may be headed for harder times.

I've made the stocks of both AIG and GM top-ten holdings because I see them as classic values.

Mutual-fund managers who beat the market for a time have a nasty habit of reverting to the mean.

My final four for the New Year's portfolio include J.C. Penney, Ashland, Motorola Solutions and the Brick.